AIMS: The Environmental Determinants of Diabetes in the Young (TEDDY) study seeks to identify environmental factors influencing the development of type 1 diabetes (T1D) using intensive follow-up of children at elevated genetic risk. This study requires a cost-effective yet accurate screening strategy to identify the high-risk cohort. METHODS: The TEDDY cohort was identified through newborn screening using human leukocyte antigen (HLA) class II genes based on criteria established with pre-TEDDY data. HLA typing was completed at six international centers using different genotyping methods that can achieve >98% accuracy. RESULTS: TEDDY developed separate inclusion criteria for the general population (GP) and first-degree relatives (FDRs) of T1D patients. The FDR eligibility includes nine haplogenotypes (DR3/4, DR4/4, DR4/8, DR3/3, DR4/4b, DR4/1, DR4/13, DR4/9, and DR3/9) for broad HLA diversity, whereas the GP eligibility includes only the first four haplogenotypes with DRB1*0403 as an exclusion allele. TEDDY has screened 414 714 GP infants, of which 19 906 (4.8%) were eligible, whereas 1415 of the 6333 screened FDR infants (22.2%) were eligible. High-resolution confirmation testing of the eligible subjects indicated that the low-cost and low-resolution genotyping techniques employed at the screening centers yielded an accuracy of 99%. There were considerable variations in eligibility rates among the centers for GP (3.5-7.4%) and FDR (19-32%) subjects. The eligibility rates among US ethnic groups were 0.9, 1.3, 5.0, and 6.9% for Asians, Black, Caucasians, and Hispanics, respectively. CONCLUSIONS: Different low-cost and low-resolution genotyping methods are useful for the efficient and accurate identification of a high-risk cohort for follow-up based on the TEDDY HLA inclusion criteria.
AIMS: The Environmental Determinants of Diabetes in the Young (TEDDY) study seeks to identify environmental factors influencing the development of type 1 diabetes (T1D) using intensive follow-up of children at elevated genetic risk. This study requires a cost-effective yet accurate screening strategy to identify the high-risk cohort. METHODS: The TEDDY cohort was identified through newborn screening using human leukocyte antigen (HLA) class II genes based on criteria established with pre-TEDDY data. HLA typing was completed at six international centers using different genotyping methods that can achieve >98% accuracy. RESULTS: TEDDY developed separate inclusion criteria for the general population (GP) and first-degree relatives (FDRs) of T1D patients. The FDR eligibility includes nine haplogenotypes (DR3/4, DR4/4, DR4/8, DR3/3, DR4/4b, DR4/1, DR4/13, DR4/9, and DR3/9) for broad HLA diversity, whereas the GP eligibility includes only the first four haplogenotypes with DRB1*0403 as an exclusion allele. TEDDY has screened 414 714 GP infants, of which 19 906 (4.8%) were eligible, whereas 1415 of the 6333 screened FDR infants (22.2%) were eligible. High-resolution confirmation testing of the eligible subjects indicated that the low-cost and low-resolution genotyping techniques employed at the screening centers yielded an accuracy of 99%. There were considerable variations in eligibility rates among the centers for GP (3.5-7.4%) and FDR (19-32%) subjects. The eligibility rates among US ethnic groups were 0.9, 1.3, 5.0, and 6.9% for Asians, Black, Caucasians, and Hispanics, respectively. CONCLUSIONS: Different low-cost and low-resolution genotyping methods are useful for the efficient and accurate identification of a high-risk cohort for follow-up based on the TEDDY HLA inclusion criteria.
Authors: Bart J Van der Auwera; Frans C Schuit; Ilse Weets; Ann Ivens; Jan E Van Autreve; Frans K Gorus Journal: Hum Immunol Date: 2002-01 Impact factor: 2.850
Authors: Mikael Knip; Riitta Veijola; Suvi M Virtanen; Heikki Hyöty; Outi Vaarala; Hans K Akerblom Journal: Diabetes Date: 2005-12 Impact factor: 9.461
Authors: A Kupila; P Muona; T Simell; P Arvilommi; H Savolainen; A M Hämäläinen; S Korhonen; T Kimpimäki; M Sjöroos; J Ilonen; M Knip; O Simell Journal: Diabetologia Date: 2001-03 Impact factor: 10.122
Authors: Deborah J Smyth; Jason D Cooper; Rebecca Bailey; Sarah Field; Oliver Burren; Luc J Smink; Cristian Guja; Constantin Ionescu-Tirgoviste; Barry Widmer; David B Dunger; David A Savage; Neil M Walker; David G Clayton; John A Todd Journal: Nat Genet Date: 2006-05-14 Impact factor: 38.330
Authors: Emily Wion; Michael Brantley; Jeff Stevens; Susan Gallinger; Hui Peng; Michael Glass; William Hagopian Journal: Ann N Y Acad Sci Date: 2003-11 Impact factor: 5.691
Authors: Andreas Beyerlein; Xiang Liu; Ulla M Uusitalo; Minna Harsunen; Jill M Norris; Kristina Foterek; Suvi M Virtanen; Marian J Rewers; Jin-Xiong She; Olli Simell; Åke Lernmark; William Hagopian; Beena Akolkar; Anette-G Ziegler; Jeffrey P Krischer; Sandra Hummel Journal: Am J Clin Nutr Date: 2015-07-08 Impact factor: 7.045
Authors: Özkan Aydemir; Janelle A Noble; Jeffrey A Bailey; Åke Lernmark; Patrick Marsh; Agnes Andersson Svärd; Frank Bearoff; Elizabeth P Blankenhorn; John P Mordes Journal: Diabetes Date: 2019-04-08 Impact factor: 9.461
Authors: Jeffrey P Krischer; Kristian F Lynch; Desmond A Schatz; Jorma Ilonen; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Ezio Bonifacio Journal: Diabetologia Date: 2015-02-10 Impact factor: 10.122
Authors: Andrea K Steck; Fran Dong; Brigitte I Frohnert; Kathleen Waugh; Michelle Hoffman; Jill M Norris; Marian J Rewers Journal: J Autoimmun Date: 2018-02-01 Impact factor: 7.094
Authors: Polly J Bingley; Diane K Wherrett; Ann Shultz; Lisa E Rafkin; Mark A Atkinson; Carla J Greenbaum Journal: Diabetes Care Date: 2018-04 Impact factor: 19.112